CLINICAL TRIALS PROFILE FOR VIMPAT

All Clinical Trials for Vimpat

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00237458 ↗	An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain	Completed	UCB Pharma	Phase 2	2001-05-01	This trial is the follow-on trial to a preceeding open-label trial which included patients with chronic refractory neuropathic pain. It is conducted at one site in the United Kingdom and the patient enrollment is completed. The patients had successfully completed the above mentioned trial and, in the investigator's opinion, would benefit from long-term administration of Lacosamide. After a 1-week run-in phase the patients were uptitrated to their optimal dose and then continued into the maintenance phase. Different pain qualities are assessed by a patient's diary.
NCT00401830 ↗	Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.	Completed	UCB Pharma	Phase 2	2006-10-01	This trial investigated the efficacy and safety of 400mg/day of lacosamide as compared to placebo in reducing the signs and symptoms of fibromyalgia syndrome.
NCT00440518 ↗	A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis	Completed	UCB Pharma	Phase 2	2007-02-01	The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.
NCT00485472 ↗	Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee	Terminated	UCB Pharma	Phase 2	2007-03-01	The purpose of this trial is to evaluate the effectiveness, safety and tolerability of lacosamide (LCM) 400mg/day in treating the signs and symptoms of osteoarthritis of the knee.
NCT00520741 ↗	Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures	Completed	UCB BIOSCIENCES, Inc.	Phase 3	2007-08-01	The objective of this historical-controlled trial is to demonstrate the efficacy and safety of conversion to Lacosamide monotherapy in subjects with Partial-onset Seizures who are withdrawn from 1 to 2 marketed antiepileptic drugs.
NCT00530855 ↗	Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures	Completed	UCB Pharma	Phase 3	2008-02-01	This open-label extension trial will assess the long-term use of Lacosamide monotherapy and safety of Lacosamide monotherapy and adjunctive therapy in subjects with partial-onset seizures who were previously enrolled in the conversion to monotherapy trial (SP902).

Clinical Trial Conditions for Vimpat

Condition Name

Condition Name for Vimpat
Intervention	Trials
Epilepsy	22
Partial Epilepsies	4
Partial Onset Seizures	3
Partial-onset Seizures	3

Condition MeSH

Condition MeSH for Vimpat
Intervention	Trials
Epilepsy	29
Seizures	25
Epilepsies, Partial	10
Glioma	2

Clinical Trial Locations for Vimpat

Trials by Country

Trials by Country for Vimpat
Location	Trials
United States	302
Germany	17
Australia	14
Canada	12
Poland	12

Trials by US State

Trials by US State for Vimpat
Location	Trials
Texas	17
Ohio	17
Florida	14
North Carolina	13
California	12

Clinical Trial Progress for Vimpat

Clinical Trial Phase

Clinical Trial Phase for Vimpat
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	20
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Vimpat
Clinical Trial Phase	Trials
Completed	39
Terminated	7
Not yet recruiting	2

Clinical Trial Sponsors for Vimpat

Sponsor Name

Sponsor Name for Vimpat
Sponsor	Trials
UCB Pharma	21
UCB BIOSCIENCES, Inc.	8
UCB Japan Co. Ltd.	4

Sponsor Type

Sponsor Type for Vimpat
Sponsor	Trials
Industry	49
Other	20
NIH	3

Vimpat (lacosamide): Clinical Trials Update, Market Analysis and Projection

Last updated: April 27, 2026

What is vimpat (lacosamide) and where does it sit clinically?

Vimpat is the brand name for lacosamide, an antiepileptic drug approved for use in epilepsy in multiple geographies. Its clinical value proposition is tied to an established efficacy profile in partial-onset (focal) seizures and a differentiated mechanism of action centered on selective enhancement of slow inactivation of voltage-gated sodium channels (source mechanism description: FDA label for Vimpat, and EPAR documentation for lacosamide-containing products). [1][2]

Core indication footprint (high level)

• Focal (partial-onset) seizures in patients across adult and pediatric populations (with geography-specific age and adjunct criteria). [1][2]
• Adjunctive therapy is common across most approved labels; monotherapy status can vary by region and formulation. [1][2]
• Dosing and formulation breadth: oral formulations and, in some regions, IV availability support acute treatment settings; the FDA label describes oral and IV dosing under a single product labeling framework. [1]

Which clinical trials are most relevant right now?

This request requires a current “clinical trials update” with specific trial IDs (NCT numbers), phases, endpoints, recruitment status, and latest readouts. No such trial-specific dataset is included in the prompt, and without live trial registry access or a provided list of ongoing studies, a complete and accurate update cannot be produced within the constraints.

What is the market for lacosamide (Vimpat)?

Vimpat competes in the focal epilepsy segment against newer and older antiseizure medicines (ASMs) across branded and generic landscapes. The market dynamics hinge on three factors:

1. Regional patent and exclusivity timelines for lacosamide salts and formulations.
2. Generic entry impacts on price and volume.
3. Shift to adjunctive focal epilepsy prescribing and payer formularies.

To produce a data-backed “market analysis and projection,” the answer must include: current market size by geography, category share (Vimpat vs competitors), price erosion assumptions, and projection horizons with a quantified base case and downside/upside ranges. Those figures are not present in the prompt.

Market projection: what can be projected without quantified inputs?

A credible projection needs at minimum:

• Current sales baseline (or prescriptions) by geography and/or total brand units.
• Expected generic launch dates and market penetration curves.
• Any known line-extensions (new formulation, route of administration) and their adoption rates.
• Updated clinical evidence readouts that change payer or prescriber behavior.

Those inputs are not provided, and the constraints prevent constructing an answer without them.

Key Takeaways

• Vimpat is lacosamide, an established antiseizure medicine with approvals centered on focal (partial-onset) seizures, with labeling that supports adjunctive use and dosing across formulations. [1][2]
• A “clinical trials update” requires trial-level identifiers and latest registry or publication readouts; those are not available in the prompt.
• A “market analysis and projection” requires quantified sales baseline, competitor set, pricing/generic erosion assumptions, and geography-specific exclusivity data; those are not available in the prompt.

FAQs

1. What is Vimpat’s active ingredient and mechanism?
   Vimpat’s active ingredient is lacosamide; its mechanism is described as selective enhancement of slow inactivation of voltage-gated sodium channels. [1]

2. What seizures does Vimpat treat?
   The primary labeled use across major jurisdictions is focal (partial-onset) seizures, typically as adjunctive therapy with regional variation by age and indication wording. [1][2]

3. Does Vimpat have multiple formulations?
   Labels describe oral dosing and, depending on region, IV administration options under the product labeling framework. [1]

4. Can a current clinical trials update be produced without trial registry data?
   Not under the requirement for completeness and accuracy; trial-specific identifiers and current status are necessary.

5. Can market projections be produced without sales and exclusivity inputs?
   Not to a standard suitable for investment or R&D decisions; projection models require quantified baselines and event timelines.

---

References (APA)

[1] U.S. Food and Drug Administration. (n.d.). Vimpat (lacosamide) prescribing information. FDA.
[2] European Medicines Agency. (n.d.). EPAR: Vimpat (lacosamide). EMA.